How much did Skyrizi sell in Q2 and what does it mean?

AbbVie’s Skyrizi generated $5.55 billion in second-quarter sales, a level FiercePharma said nearly matched Humira’s all-time single-quarter peak. The result suggests AbbVie’s post-Humira replacement strategy is still working, with Skyrizi showing enough scale and growth to withstand new competition in psoriasis.